Annual General Meeting to be held on August 8, 2025
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors approved audited financial results for Q4 and FY ended March 31, 2025, with a clean (unmodified) opinion from statutory auditor Kalyaniwalla & Mistry LLP. Standalone FY25 revenue from operations rose about 15% to Rs. 88,649 lakh, but the company reported a standalone loss before tax of Rs. 12,343 lakh, mainly due to impairments in subsidiaries. On a consolidated basis, FY25 revenue grew ~15% to Rs. 166,653 lakh with profit from continuing operations at Rs. 4,947 lakh, but a Rs. 20,752 lakh loss from discontinued operations (CFS Europe SPA, Italy and CFS Wanglong Flavors, China) pulled the total into a loss. The 32nd AGM is set for August 8, 2025. The Board also approved liquidation of CFS Wanglong Flavors (Ningbo) and Europe Bio Engineering BV (Belgium), and a reverse merger of CFS De Mexico Blends into Dresen Quimica with effect from Feb 28, 2025.
Investors get clarity on a mixed year: solid topline growth on both standalone and consolidated bases, but bottom-line hurt by one-time impairments and discontinued operations. The undisclosed embezzlement of Rs. 640.48 lakh at Britec SA (Guatemala) and the wind-down of unviable units signal management's cleanup phase, which could be neutral to mildly positive if costs stabilize going forward.